Pharmacy

Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.

As of July 1, the FDA had 4,036 generic drug applications awaiting approval; median time it takes for the FDA to approve a generic is now 47 months.

Mylan said Monday it will offer a generic version of the life-saving allergy treatment following weeks of criticism over price hike.

The Prescription Drug Monitoring Program aims to combat drug abuse in the state.

Report describes steps states can take to address a number of drug-coverage issues in the commercial insurance market.

Responding to pressure from lawmakers and the public, Mylan Pharmaceutical is expanding existing programs to make its EpiPen emergency allergy treatments more affordable.

Lawmakers are imploring Mylan Pharmaceutical, the manufacturer of EpiPens, to scale back price increases that have seen the cost of the life-saving emergency allergy treatment swell from $100 to $600 per package, according to published reports.

The "most important factor" that drives prescription drug prices higher in the United States than anywhere else in the world is the existence of government-protected "monopoly" rights for drug manufacturers, researchers at Harvard Medical School reported today.

XTANDI has been used to treat 64,000 men with prostate cancer to date and has generated $2.2 billion in sales.

A preliminary analysis by from the CVS Health Research Institute in fact shows that payers could save approximately $38 to $63 million per 100,000 members.